Viard JP - Search Results

1

Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects.

Zylberberg H, Chaix ML, Rabian C, Rouzioux C, Aulong B, Bréchot C, Viard JP, Pol S. Zylberberg H, et al. Among authors: viard jp. Clin Infect Dis. 1998 May;26(5):1104-6. doi: 10.1086/520281. Clin Infect Dis. 1998. PMID: 9597236

2

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.

Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group. Raymond S, et al. Clin Infect Dis. 2018 May 2;66(10):1588-1594. doi: 10.1093/cid/cix1070. Clin Infect Dis. 2018. PMID: 29244143 Free PMC article.

3

Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus.

Zylberberg H, Vargaftig J, Barbieux C, Pertuiset N, Rothschild C, Viard JP. Zylberberg H, et al. Among authors: viard jp. Clin Infect Dis. 1996 Sep;23(3):641-3. doi: 10.1093/clinids/23.3.641. Clin Infect Dis. 1996. PMID: 8879797 No abstract available.

4

Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma.

Vittecoq D, Mattlinger B, Barre-Sinoussi F, Courouce AM, Rouzioux C, Doinel C, Bary M, Viard JP, Bach JF, Rouger P, et al. Vittecoq D, et al. Among authors: viard jp. J Infect Dis. 1992 Feb;165(2):364-8. doi: 10.1093/infdis/165.2.364. J Infect Dis. 1992. PMID: 1730902 Clinical Trial.

5

No evidence for proliferation in the blood CD4+ T-cell pool during HIV-1 infection and triple combination therapy.

Tissot O, Viard JP, Rabian C, Ngo N, Burgard M, Rouzioux C, Penit C. Tissot O, et al. Among authors: viard jp. AIDS. 1998 May 28;12(8):879-84. doi: 10.1097/00002030-199808000-00010. AIDS. 1998. PMID: 9631141

6

Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy.

Jubault V, Pacanowski J, Rabian C, Viard JP. Jubault V, et al. Among authors: viard jp. Ann Med Interne (Paris). 2000 May;151(3):163-8. Ann Med Interne (Paris). 2000. PMID: 10896967

7

Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.

Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP. Rakotoambinina B, et al. Among authors: viard jp. J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):443-9. doi: 10.1097/00126334-200108150-00004. J Acquir Immune Defic Syndr. 2001. PMID: 11511820

8

Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy.

Weiss L, Burgard M, Cahen YD, Chaix ML, Laureillard D, Gilquin J, Piketty C, Viard JP, Kazatchkine MD, Girard PM, Rouzioux C. Weiss L, et al. Among authors: viard jp. HIV Med. 2002 Jan;3(1):12-20. doi: 10.1046/j.1464-2662.2001.00095.x. HIV Med. 2002. PMID: 12059946 Free article.

9

Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

Delaugerre C, Buyck JF, Peytavin G, Viard JP, Chaix ML, Zucman D, Mortier E, Blanche S, Rouveix E, Force G, Aegerter P, de Truchis P. Delaugerre C, et al. Among authors: viard jp. J Clin Virol. 2010 Mar;47(3):248-52. doi: 10.1016/j.jcv.2009.12.022. Epub 2010 Jan 22. J Clin Virol. 2010. PMID: 20097121

10

Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: Underestimation of some CRF02 strains.

Avettand-Fénoël V, Mélard A, Gueudin M, Maillard A, Dina J, Gousset M, Chaix ML, Lerolle N, Viard JP, Meyer L, Plantier JC, Rouzioux C; ANRS-AC11 HIV Quantification Working Group. Avettand-Fénoël V, et al. Among authors: viard jp. J Clin Virol. 2019 Jan;110:36-41. doi: 10.1016/j.jcv.2018.12.002. Epub 2018 Dec 3. J Clin Virol. 2019. PMID: 30530097

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

395 results

Search Page

Filters